1
|
Woźniak M, Konopka CJ, Płoska A, Hedhli J, Siekierzycka A, Banach M, Bartoszewski R, Dobrucki LW, Kalinowski L, Dobrucki IT. Molecularly targeted nanoparticles: an emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease. Cell Mol Biol Lett 2021; 26:10. [PMID: 33726678 PMCID: PMC7968326 DOI: 10.1186/s11658-021-00253-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 03/02/2021] [Indexed: 12/15/2022] Open
Abstract
Background Molecular imaging with molecularly targeted probes is a powerful tool for studying the spatio-temporal interactions between complex biological processes. The pivotal role of the receptor for advanced glycation end products (RAGE), and its involvement in numerous pathological processes, aroused the demand for RAGE-targeted imaging in various diseases. In the present study, we evaluated the use of a diagnostic imaging agent for RAGE quantification in an animal model of peripheral artery disease, a multimodal dual-labeled probe targeted at RAGE (MMIA-CML). Methods PAMAM dendrimer was conjugated with Nε-carboxymethyl-lysine (CML) modified albumin to synthesize the RAGE-targeted probe. A control untargeted agent carried native non-modified human albumin (HSA). Bifunctional p-SCN-Bn-NOTA was used to conjugate the 64Cu radioisotope. Surgical right femoral artery ligation was performed on C57BL/6 male mice. One week after femoral artery ligation, mice were injected with MMIA-CML or MMIA-HSA labeled with 64Cu radioisotope and 60 min later in vivo microPET-CT imaging was performed. Immediately after PET imaging studies, the murine hindlimb muscle tissues were excised and prepared for gene and protein expression analysis. RAGE gene and protein expression was assessed using real-time qPCR and Western blot technique respectively. To visualize RAGE expression in excised tissues, microscopic fluorescence imaging was performed using RAGE-specific antibodies and RAGE-targeted and -control MMIA. Results Animals subjected to PET imaging exhibited greater MMIA-CML uptake in ischemic hindlimbs than non-ischemic hindlimbs. We observed a high correlation between fluorescent signal detection and radioactivity measurement. Significant RAGE gene and protein overexpression were observed in ischemic hindlimbs compared to non-ischemic hindlimbs at one week after surgical ligation. Fluorescence microscopic staining revealed significantly increased uptake of RAGE-targeted nanoparticles in both ischemic and non-ischemic muscle tissues compared to the control probe but at a higher level in ischemic hindlimbs. Ischemic tissue exhibited explicit RAGE dyeing following anti-RAGE antibody and high colocalization with the MMIA-CML targeted at RAGE. Conclusions The present results indicate increased expression of RAGE in the ischemic hindlimb and enable the use of multimodal nanoparticles in both in vitro and in vivo experimental models, creating the possibility for imaging structural and functional changes with a RAGE-targeted tracer. Supplementary Information The online version contains supplementary material available at 10.1186/s11658-021-00253-0.
Collapse
Affiliation(s)
- Marcin Woźniak
- Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland.,University of Illinois at Urbana-Champaign Beckman Institute for Advanced Science and Technology, 405 N Mathews Ave, MC-251, 61801 Urbana, IL, USA
| | - Christian J Konopka
- University of Illinois at Urbana-Champaign Beckman Institute for Advanced Science and Technology, 405 N Mathews Ave, MC-251, 61801 Urbana, IL, USA.,Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Agata Płoska
- Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland.,Biobanking and Biomolecular Resources Research Infrastructure Poland (BBMRI.pl), Gdansk, Poland
| | - Jamila Hedhli
- University of Illinois at Urbana-Champaign Beckman Institute for Advanced Science and Technology, 405 N Mathews Ave, MC-251, 61801 Urbana, IL, USA
| | - Anna Siekierzycka
- Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland
| | - Maciej Banach
- Department of Hypertension, Medical University of Lodz, Lodz, Poland
| | - Rafal Bartoszewski
- Department of Biology and Pharmaceutical Botany, Medical University of Gdansk, Gdansk, Poland
| | - Lawrence W Dobrucki
- Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland.,University of Illinois at Urbana-Champaign Beckman Institute for Advanced Science and Technology, 405 N Mathews Ave, MC-251, 61801 Urbana, IL, USA.,Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.,Biobanking and Biomolecular Resources Research Infrastructure Poland (BBMRI.pl), Gdansk, Poland.,Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, IL, USA.,Carle-Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Leszek Kalinowski
- Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland. .,Biobanking and Biomolecular Resources Research Infrastructure Poland (BBMRI.pl), Gdansk, Poland. .,BioTechMed Centre, Department of Mechanics of Materials and Structures, Gdansk University of Technology, Gdansk, Poland.
| | - Iwona T Dobrucki
- University of Illinois at Urbana-Champaign Beckman Institute for Advanced Science and Technology, 405 N Mathews Ave, MC-251, 61801 Urbana, IL, USA. .,Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
| |
Collapse
|
2
|
Pant K, Sedláček O, Nadar RA, Hrubý M, Stephan H. Radiolabelled Polymeric Materials for Imaging and Treatment of Cancer: Quo Vadis? Adv Healthc Mater 2017; 6. [PMID: 28218487 DOI: 10.1002/adhm.201601115] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 11/24/2016] [Indexed: 12/15/2022]
Abstract
Owing to their tunable blood circulation time and suitable plasma stability, polymer-based nanomaterials hold a great potential for designing and utilising multifunctional nanocarriers for efficient imaging and effective treatment of cancer. When tagged with appropriate radionuclides, they may allow for specific detection (diagnosis) as well as the destruction of tumours (therapy) or even customization of materials, aiming to both diagnosis and therapy (theranostic approach). This review provides an overview of recent developments of radiolabelled polymeric nanomaterials (natural and synthetic polymers) for molecular imaging of cancer, specifically, applying nuclear techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Different approaches to radiolabel polymers are evaluated from the methodical radiochemical point of view. This includes new bifunctional chelating agents (BFCAs) for radiometals as well as novel labelling methods. Special emphasis is given to eligible strategies employed to evade the mononuclear phagocytic system (MPS) in view of efficient targeting. The discussion encompasses promising strategies currently employed as well as emerging possibilities in radionuclide-based cancer therapy. Key issues involved in the clinical translation of radiolabelled polymers and future scopes of this intriguing research field are also discussed.
Collapse
Affiliation(s)
- Kritee Pant
- Helmholtz-Zentrum Dresden-Rossendorf; Institute of Radiopharmaceutical Cancer Research; Bautzner Landstraße 400 01328 Dresden Germany
| | - Ondřej Sedláček
- Institute of Macromolecular Chemistry; The Academy of Sciences of the Czech Republic; Heyrovského námeˇstí 2 16206 Prague 6 Czech Republic
| | - Robin A. Nadar
- Helmholtz-Zentrum Dresden-Rossendorf; Institute of Radiopharmaceutical Cancer Research; Bautzner Landstraße 400 01328 Dresden Germany
| | - Martin Hrubý
- Institute of Macromolecular Chemistry; The Academy of Sciences of the Czech Republic; Heyrovského námeˇstí 2 16206 Prague 6 Czech Republic
| | - Holger Stephan
- Helmholtz-Zentrum Dresden-Rossendorf; Institute of Radiopharmaceutical Cancer Research; Bautzner Landstraße 400 01328 Dresden Germany
| |
Collapse
|
3
|
Silva Adaya D, Aguirre-Cruz L, Guevara J, Ortiz-Islas E. Nanobiomaterials' applications in neurodegenerative diseases. J Biomater Appl 2016; 31:953-984. [PMID: 28178902 DOI: 10.1177/0885328216659032] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The blood-brain barrier is the interface between the blood and brain, impeding the passage of most circulating cells and molecules, protecting the latter from foreign substances, and maintaining central nervous system homeostasis. However, its restrictive nature constitutes an obstacle, preventing therapeutic drugs from entering the brain. Usually, a large systemic dose is required to achieve pharmacological therapeutic levels in the brain, leading to adverse effects in the body. As a consequence, various strategies are being developed to enhance the amount and concentration of therapeutic compounds in the brain. One such tool is nanotechnology, in which nanostructures that are 1-100 nm are designed to deliver drugs to the brain. In this review, we examine many nanotechnology-based approaches to the treatment of neurodegenerative diseases. The review begins with a brief history of nanotechnology, followed by a discussion of its definition, the properties of most reported nanomaterials, their biocompatibility, the mechanisms of cell-material interactions, and the current status of nanotechnology in treating Alzheimer's, Parkinson's diseases, and amyotrophic lateral sclerosis. Of all strategies to deliver drug to the brain that are used in nanotechnology, drug release systems are the most frequently reported.
Collapse
Affiliation(s)
- Daniela Silva Adaya
- 1 Experimental Laboratory for Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Manuel Velasco Suárez, México City, Mexico
| | - Lucinda Aguirre-Cruz
- 2 Laboratory of Neuroimmunoendocrinology, National Institute of Neurology and Neurosurgery, Manuel Velasco Suárez, México City, Mexico
| | - Jorge Guevara
- 3 Biochemistry Department, Faculty of Medicine, National Autonomous University of Mexico, Mèxico City, Mexico
| | - Emma Ortiz-Islas
- 4 Nanotechnology Laboratory, National Institute of Neurology and Neurosurgery, México City, Manuel Velasco Suárez, Mexico
| |
Collapse
|
4
|
Narsireddy A, Vijayashree K, Adimoolam MG, Manorama SV, Rao NM. Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy. Int J Nanomedicine 2015; 10:6865-78. [PMID: 26604753 PMCID: PMC4639554 DOI: 10.2147/ijn.s89474] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Challenges in photodynamic therapy (PDT) include development of efficient near infrared-sensitive photosensitizers (5,10,15,20-tetrakis(4-hydroxyphenyl)-21H,23H-porphine [PS]) and targeted delivery of PS to the tumor tissue. In this study, a dual functional dendrimer was synthesized for targeted PDT. For targeting, a poly(amidoamine) dendrimer (G4) was conjugated with a PS and a nitrilotriacetic acid (NTA) group. A peptide specific to human epidermal growth factor 2 was expressed in Escherichia coli with a His-tag and was specifically bound to the NTA group on the dendrimer. Reaction conditions were optimized to result in dendrimers with PS and the NTA at a fractional occupancy of 50% and 15%, respectively. The dendrimers were characterized by nuclear magnetic resonance, matrix-assisted laser desorption/ionization, absorbance, and fluorescence spectroscopy. Using PS fluorescence, cell uptake of these particles was confirmed by confocal microscopy and fluorescence-activated cell sorting. PS-dendrimers are more efficient than free PS in PDT-mediated cell death assays in HER2 positive cells, SK-OV-3. Similar effects were absent in HER2 negative cell line, MCF-7. Compared to free PS, the PS-dendrimers have shown significant tumor suppression in a xenograft animal tumor model. Conjugation of a PS with dendrimers and with a targeting agent has enhanced photodynamic therapeutic effects of the PS.
Collapse
Affiliation(s)
| | | | | | | | - Nalam M Rao
- CSIR - Centre for Cellular and Molecular Biology, Hyderabad, India
| |
Collapse
|
5
|
Niki Y, Ogawa M, Makiura R, Magata Y, Kojima C. Optimization of dendrimer structure for sentinel lymph node imaging: Effects of generation and terminal group. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 11:2119-27. [DOI: 10.1016/j.nano.2015.08.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2015] [Revised: 08/04/2015] [Accepted: 08/18/2015] [Indexed: 10/23/2022]
|
6
|
Ayatollahi S, Hashemi M, Kazemi Oskuee R, Salmasi Z, Mokhtarzadeh A, Alibolandi M, Abnous K, Ramezani M. Synthesis of efficient gene delivery systems by grafting pegylated alkylcarboxylate chains to PAMAM dendrimers: Evaluation of transfection efficiency and cytotoxicity in cancerous and mesenchymal stem cells. J Biomater Appl 2015; 30:632-48. [DOI: 10.1177/0885328215599667] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The applications of polyamidoamine (PAMAM) dendrimers have attracted much attention in biomedicine specially non-viral gene delivery because of thier unique characteristics including hyperbranching, multivalency, and well-defined uniform globular three-dimensional structures. In the current study, in order to enhance the transfection efficiency and reduce the cytotoxicity of PAMAMs, bromoalkylcarboxylates with different chain length (2-bromoacetic, 6-bromohexanoic, 10-bromodecanoic and 16-bromohexadecanoic acids) were covalently conjugated with 10% and 30% of primary amines of generation 4 and 5 (G4 and G5) of PAMAM dendrimers to increase the hydrophobicity of the carrier. At the next stage, the alkylcarboxylate-PAMAMs were pegylaed to further modify the PAMAM structures for biological applications. Obtained results demonstrated that the prepared PAMAM derivatives had particle size around 140 nm with net-positive surface charge. None of the prepared PAMAM-based non-viral vactors exhibited significant hemolytic activity and also cytotoxicity. Meanwhile decahexanoate–PAMAM G4 [G4(16C-10%)] and decanoate–PAMAM G4 conjugated to polyethylene glycol (PEG) (G4[(10C-30%)(10C-PEG)]) showed highest transfection efficiency in murine neuroblastoma (Neuro-2a) cell line, interestingly only the latter had improved transfection efficiency in mesenchymal stem cells (MSCs). This study proved the potential utility of alkylcarboxylate-grafted PAMAM dendrimers (G4 and G5) with or without PEG modification for efficient gene transfer into cancerous cells as well as MSCs.
Collapse
Affiliation(s)
- Sara Ayatollahi
- Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Maryam Hashemi
- Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Reza Kazemi Oskuee
- Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Zahra Salmasi
- Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Ahad Mokhtarzadeh
- Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
- School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran
| | - Mona Alibolandi
- Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Khalil Abnous
- Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mohammad Ramezani
- Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
7
|
Bajwa N, Mehra NK, Jain K, Jain NK. Pharmaceutical and biomedical applications of quantum dots. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2015; 44:758-68. [PMID: 26058404 DOI: 10.3109/21691401.2015.1052468] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Quantum dots (QDs) have captured the fascination and attention of scientists due to their simultaneous targeting and imaging potential in drug delivery, in pharmaceutical and biomedical applications. In the present study, we have exhaustively reviewed various aspects of QDs, highlighting their pharmaceutical and biomedical applications, pharmacology, interactions, and toxicological manifestations. The eventual use of QDs is to dramatically improve clinical diagnostic tests for early detection of cancer. In recent years, QDs were introduced to cell biology as an alternative fluorescent probe.
Collapse
Affiliation(s)
- Neha Bajwa
- a Department of Pharmaceutics , Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy , Moga , Punjab , India
| | - Neelesh K Mehra
- a Department of Pharmaceutics , Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy , Moga , Punjab , India
| | - Keerti Jain
- a Department of Pharmaceutics , Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy , Moga , Punjab , India
| | - Narendra K Jain
- a Department of Pharmaceutics , Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy , Moga , Punjab , India
| |
Collapse
|
8
|
|
9
|
Zhao Y, Zhao J, Li R, Han M, Zhu C, Wang M, Guo Y, Wang X. A series of codendrimers from polyamidoamine (PAMAM) and oligoethylene glycols (OEG) dendrons as drug carriers: the effect of OEG dendron decoration degree. RSC Adv 2015. [DOI: 10.1039/c5ra12177a] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
To evaluate the effect of OEG dendron decoration degree and find a suitable carrier, a series of codendrimers are prepared and utilized to transport methotrexate.
Collapse
Affiliation(s)
- Yanna Zhao
- Institute of Medicinal Plant Development
- Chinese Academy of Medical Sciences & Peking Union Medical College
- Beijing 100193
- P. R. China
| | - Jing Zhao
- The College of Chemistry and Molecular Engineering
- Zhengzhou University
- Zhengzhou
- P. R. China
| | - Ran Li
- Institute of Medicinal Plant Development
- Chinese Academy of Medical Sciences & Peking Union Medical College
- Beijing 100193
- P. R. China
| | - Meihua Han
- Institute of Medicinal Plant Development
- Chinese Academy of Medical Sciences & Peking Union Medical College
- Beijing 100193
- P. R. China
| | - Chunyan Zhu
- Institute of Medicinal Plant Development
- Chinese Academy of Medical Sciences & Peking Union Medical College
- Beijing 100193
- P. R. China
| | - Mincan Wang
- The College of Chemistry and Molecular Engineering
- Zhengzhou University
- Zhengzhou
- P. R. China
| | - Yifei Guo
- Institute of Medicinal Plant Development
- Chinese Academy of Medical Sciences & Peking Union Medical College
- Beijing 100193
- P. R. China
| | - Xiangtao Wang
- Institute of Medicinal Plant Development
- Chinese Academy of Medical Sciences & Peking Union Medical College
- Beijing 100193
- P. R. China
| |
Collapse
|
10
|
Lee C, Lo ST, Lim J, da Costa VCP, Ramezani S, Öz OK, Pavan GM, Annunziata O, Sun X, Simanek EE. Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. Mol Pharm 2013; 10:4452-61. [PMID: 24134039 DOI: 10.1021/mp400290u] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The synthesis and characterization of a generation three triazine dendrimer that displays a phenolic group at the core for labeling, up to eight 5 kDa PEG chains for solubility, and 16 paclitaxel groups is described. Three different diamine linkers--dipiperidine trismethylene, piperazine, and aminomethylpiperidine--were used within the dendrimer. To generate the desired stoichiometric ratio of 8 PEG chains to 16 paclitaxel groups, a monochlorotriazine was prepared with two paclitaxel groups attached through their 2'-hydroxyls using a linker containing a labile disulfide. This monochlorotriazine was linked to a dichlorotriazine with aminomethylpiperidine. The resulting dichlorotriazine bearing two paclitaxel groups could be reacted with the eight amines of the dendrimer. NMR and MALDI-TOF confirm successful reaction. The eight monochlorotriazines of the resulting material are used as the site for PEGylation affording the desired 2:1 stoichiometry. The target and intermediates were amenable to characterization by (1)H and (13)C NMR, and mass spectrometry. Analysis revealed that 16 paclitaxel groups were installed along with 5-8 PEG chains. The final construct is 63% PEG, 22% paclitaxel, and 15% triazine dendrimer. Consistent with previous efforts and computational models, 5 kDa PEG groups were essential for making the target water-soluble. Molecular dynamics simulations showed a high degree of hydration of the core, and a radius of gyration of 2.8 ± 0.2 nm. The hydrodynamic radius of the target was found to be 15.8 nm by dynamic light scattering, an observation indicative of aggregation. Drug release studies performed in plasma showed slow and identical release in mouse and rat plasma (8%, respectively). SPECT/CT imaging was used to follow biodistribution and tumor uptake. Using a two component model, the elimination and distribution half-lives were 2.65 h and 38.2 h, respectively. Compared with previous constructs, this dendrimer persists in the vasculature longer (17.33 ± 0.88% ID/g at 48 h postinjection), and showed higher tumor uptake. Low levels of dendrimer were observed in lung, liver, and spleen (~6% ID/g). Tumor saturation studies of small prostate cancer tumors (PC3) suggest that saturation occurs at a dose between 23.2 mg/kg and 70.9 mg/kg.
Collapse
Affiliation(s)
- Changsuk Lee
- Department of Chemistry, Texas Christian University , Fort Worth, Texas 76129, United States
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Yanagi M, Uehara T, Uchida Y, Kiyota S, Kinoshita M, Higaki Y, Akizawa H, Hanaoka H, Arano Y. Chemical Design of 99mTc-Labeled Probes for Targeting Osteogenic Bone Region. Bioconjug Chem 2013; 24:1248-55. [DOI: 10.1021/bc400197f] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Mashiho Yanagi
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| | - Tomoya Uehara
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| | - Yukie Uchida
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| | - Sachiko Kiyota
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| | - Mai Kinoshita
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| | - Yusuke Higaki
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| | - Hiromichi Akizawa
- Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machidashi,
Tokyo, 194-8543, Japan
| | - Hirofumi Hanaoka
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| | - Yasushi Arano
- Graduate School of Pharmaceutical
Sciences, Chiba University, 1-8-1 Inohana,
Chuo-ku, Chiba, 263-8675, Japan
| |
Collapse
|
12
|
Hamidi A, Rashidi MR, Asgari D, Aghanejad A, Davaran S. Covalent Immobilization of Trypsin on a Novel Aldehyde-Terminated PAMAM Dendrimer. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.7.2181] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
13
|
Ghobril C, Lamanna G, Kueny-Stotz M, Garofalo A, Billotey C, Felder-Flesch D. Dendrimers in nuclear medical imaging. NEW J CHEM 2012. [DOI: 10.1039/c1nj20416e] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
14
|
Cheng Y, Zhao L, Li Y, Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev 2011; 40:2673-703. [PMID: 21286593 DOI: 10.1039/c0cs00097c] [Citation(s) in RCA: 358] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
In the past decade, nanomedicine with its promise of improved therapy and diagnostics has revolutionized conventional health care and medical technology. Dendrimers and dendrimer-based therapeutics are outstanding candidates in this exciting field as more and more biological systems have benefited from these starburst molecules. Anticancer agents can be either encapsulated in or conjugated to dendrimer and be delivered to the tumour via enhanced permeability and retention (EPR) effect of the nanoparticle and/or with the help of a targeting moiety such as antibody, peptides, vitamins, and hormones. Imaging agents including MRI contrast agents, radionuclide probes, computed tomography contrast agents, and fluorescent dyes are combined with the multifunctional nanomedicine for targeted therapy with simultaneous cancer diagnosis. However, an important question reported with dendrimer-based therapeutics as well as other nanomedicines to date is the long-term viability and biocompatibility of the nanotherapeutics. This critical review focuses on the design of biocompatible dendrimers for cancer diagnosis and therapy. The biocompatibility aspects of dendrimers such as nanotoxicity, long-term circulation, and degradation are discussed. The construction of novel dendrimers with biocompatible components, and the surface modification of commercially available dendrimers by PEGylation, acetylation, glycosylation, and amino acid functionalization have been proposed as available strategies to solve the safety problem of dendrimer-based nanotherapeutics. Also, exciting opportunities and challenges on the development of dendrimer-based nanoplatforms for targeted cancer diagnosis and therapy are reviewed (404 references).
Collapse
Affiliation(s)
- Yiyun Cheng
- School of Life Sciences, East China Normal University, Shanghai, 200062, People's Republic of China.
| | | | | | | |
Collapse
|
15
|
Wijagkanalan W, Kawakami S, Hashida M. Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations. Pharm Res 2010; 28:1500-19. [DOI: 10.1007/s11095-010-0339-8] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2010] [Accepted: 11/29/2010] [Indexed: 01/14/2023]
|
16
|
Miyamoto R, Akizawa H, Nishikawa T, Uehara T, Azuma Y, Nakase I, Futaki S, Hanaoka H, Iida Y, Endo K, Arano Y. Enhanced Target-Specific Accumulation of Radiolabeled Antibodies by Conjugating Arginine-Rich Peptides as Anchoring Molecules. Bioconjug Chem 2010; 21:2031-7. [DOI: 10.1021/bc100259q] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Rei Miyamoto
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Hiromichi Akizawa
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Takeshi Nishikawa
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Tomoya Uehara
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Yusuke Azuma
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Ikuhiko Nakase
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Shiroh Futaki
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Hirofumi Hanaoka
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Yasuhiko Iida
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Keigo Endo
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| | - Yasushi Arano
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido 061-0293, Japan, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan, Graduate School of Medicine, Gunma University, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371-8511, Japan, and Suzuka University of Medical Science, 1001-1
| |
Collapse
|
17
|
Shen Y, Zhou Z, Sui M, Tang J, Xu P, Kirk EAV, Murdoch WJ, Fan M, Radosz M. Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery. Nanomedicine (Lond) 2010; 5:1205-17. [DOI: 10.2217/nnm.10.86] [Citation(s) in RCA: 92] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Aims: Polyamidoamine (PAMAM) dendrimers with primary amine termini have been extensively explored as drug and gene carriers owing to their unique properties, but their amine-carried cationic charges cause nonspecific cellular uptakes, systemic toxicity and other severe problems in in vivo applications. Method: In this article, we report a charge-reversal approach that latently deactivates PAMAM’s primary amines to negatively charged acid-labile amides in order to inhibit its nonspecific interaction with cells, but regenerates the active PAMAM once in acidic environments. Results: A cascade cancer cell nuclear drug delivery was achieved using the latently amidized PAMAM as the carrier conjugated with folic acid as the targeting group and a DNA-toxin drug camptothecin. The conjugate had low nonspecific interactions with cells, but easily entered cancer cells overexpressing folate receptors via receptor-mediated endocytosis. Subsequently, the endocytosed conjugate was transferred to acidic lysosomes, wherein the active PAMAM carrier was regenerated, escaped from the lysosome and then entered the nucleus for drug release. Conclusion: This reversible deactivation/activation makes PAMAM dendrimers useful nanocarriers for in vivo cancer cell nuclear-targeted drug delivery.
Collapse
Affiliation(s)
| | - Zhuxian Zhou
- Department of Chemical & Petroleum Engineering, University of Wyoming, Laramie, WY, 82071, USA
| | - Meihua Sui
- Center for Bionanoengineering & Department of Chemical & Biological Engineering, Zhejiang University, Hangzhou, 310027, China
| | - Jianbin Tang
- Center for Bionanoengineering & Department of Chemical & Biological Engineering, Zhejiang University, Hangzhou, 310027, China
| | - Peisheng Xu
- Department of Chemical & Petroleum Engineering, University of Wyoming, Laramie, WY, 82071, USA
- College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA
| | - Edward A Van Kirk
- Department of Animal Science, University of Wyoming, Laramie, WY, 82071, USA
| | - William J Murdoch
- Department of Animal Science, University of Wyoming, Laramie, WY, 82071, USA
| | - Maohong Fan
- Department of Chemical & Petroleum Engineering, University of Wyoming, Laramie, WY, 82071, USA
| | - Maciej Radosz
- Department of Chemical & Petroleum Engineering, University of Wyoming, Laramie, WY, 82071, USA
| |
Collapse
|